Upadacitinib Drug Survival in the Management of Patients With Moderate to Severe Atopic Dermatitis: Real-Time Data From the Biogrid Database Registry

Australas J Dermatol. 2025 Apr 18. doi: 10.1111/ajd.14469. Online ahead of print.

ABSTRACT

BACKGROUND/OBJECTIVES: Atopic dermatitis (AD) is a chronic inflammatory skin disorder significantly affecting quality of life and healthcare resources. Upadacitinib has been recently approved for ad treatment in Australia and offers a promising alternative to traditional systemic therapies. However, real-world data on their long-term effectiveness, particularly drug survival (the time from treatment initiation to discontinuation), remain scarce. This study aims to investigate the drug survival rate and factors affecting the drug survival of Upadacitinib in ad patients.

METHOD: In this retrospective analysis, we included 21 adults with moderate to severe AD from the Royal Melbourne Hospital electronic medical records. Drug survival rates were analysed using Kaplan-Meier survival estimates, reasons for discontinuation were examined, and cox-proportional analysis was utilised to investigate factors affecting drug survival.

RESULTS: Upadacitinib demonstrated a high treatment retention rate, with a survival probability of 90.5% by the end of the 4-week mark. Reasons for discontinuation included factors affecting drug survival, concurrent infections, side effects, and loss of efficacy.

CONCLUSION: These findings indicate that Upadacitinib may offer a longer-lasting treatment option with good overall retention in ad management. Real-world data such as these provide crucial insights for dermatologists in choosing appropriate therapies, potentially enhancing patient satisfaction, adherence, and long-term outcomes. Further studies with larger sample sizes and diverse populations are recommended to validate these findings and guide treatment strategies.

PMID:40248987 | DOI:10.1111/ajd.14469